Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

Clinical Chemistry

Volumn 50, Issue 9, 2004, Pages 1623-1633

  Steimer, Werner ^a   Zöpf, Konstanze ^a   Von Amelunxen, Silvia ^b   Pfeiffer, Herbert ^c   Bachofer, Julia ^a   Popp, Johannes ^a   Messner, Barbara ^a   Kissling, Werner ^b   Leucht, Stefan ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KLINIKUM MÜNCHEN OST   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; NORTRIPTYLINE;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME METABOLISM; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GENE DOSAGE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOASSAY; MALE; MULTICENTER STUDY; NULL ALLELE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; STEADY STATE; WILD TYPE;

ADULT; AGED; ALLELES; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; DEPRESSION; DNA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NORTRIPTYLINE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 4344613464     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.030825     Document Type: Article

References (43)

1. Tucker GT. Advances in understanding drug metabolism and its contribution to variability in patient response. Ther Drug Monit 2000;22:110-3.
2. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14:230-40.
3. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-21.
4. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000;61:174-83.
5. Chou W-H, Van F-X, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003;49:542-51.
6. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
7. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
8. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
9. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000;10:577-81.
10. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22.
11. Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001;11:573-85.
12. Allorge D, Harlow J, Boulet O, Hayhurst GP, Chowdry J, Roth E, et al. In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics 2001;11:739-41.
13. Lovlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001;11:45-55.
14. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72:438-52.
15. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-5.
16. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12: 465-72.
17. Wedlund PJ, de Leon J. Pharmacogenomic testing: the cost factor. Pharmacogenomics J 2001;1:171-4.
18. Steimer W, Potter JM, Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002;315:137-55.
19. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92.
20. Baumann P, Jonzier-Perey M, Koeb L, Kupfer A, Tinguely D, Schopf J. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986;1:102-12.
21. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
22. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
23. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356-61.
24. Muller B, Zopf K, Bachofer J, Steimer W. Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem 2003;49:1624-31.
25. Steimer W, Bachofer J, Leucht S, Muller B. Rapid detection of the ultraextensive metabolizer associated CYP2D6*35 polymorphism [Abstract]. Clin Chem 2002;48(Suppl 6S):A45.
26. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
27. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002;3:289-309.
28. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
29. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977;2:584-6.
30. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new Pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
31. Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993;3:123-30.
32. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993;3:256-63.
33. Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003;23:459-66.
34. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002;12:571-80.
35. Kvist EE, Al-Shurbaji A, Dahl ML, Nordin C, Alvan G, Stahle L. Quantitative Pharmacogenetics of nortriptyline: a novel approach. Clin Pharmacokinet 2001;40:869-77.
36. Murphy GM Jr, Pollock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH, et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 2001;25:737-43.
37. Wedlund PJ. Practical considerations for pharmacogenetic testing. MLO Med Lab Obs 2001;33:16-21, 23, quiz 24-5.
38. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. BMJ 2000;320:987-90.
39. Shimoda K, Someya T, Yokono A, Morita S, Hirokane G, Takahashi S, et al. Impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol 2002;22:371-8.
40. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999;147:300-5.
41. Yokono A, Morita S, Someya T, Hirokane G, Okawa M, Shimoda K. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 2001;21:549-55.
42. McElroy S, Sachse C, Brockmoller J, Richmond J, Lira M, Friedman D, et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS Pharm Sci 2000;2:E33.
43. Linder MW, Keck PE Jr. Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1073-84.